Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinson's disease

Study reports 'off time' reduced in those receiving standard dopamine therapy

2011-02-14

(Press-News.org) Tampa, FL (Feb. 10, 2011) -- Preladenant, a non-dopaminergic medication, reduces off time in patients with Parkinson's disease receiving standard dopamine therapy, an international study led by the University of South Florida found.

Results of the double-blind, randomized clinical trial are reported online today in the journal Lancet Neurology. The findings suggest that preladenant may offer a new supplemental treatment for Parkinson's disease without some of the complications of levodopa and other standard dopamine treatments.

"The goal of treatment is to provide the best possible function and quality of life to patients over time," said lead author Dr. Robert A. Hauser, director of the Parkinson's Disease and Movement Disorders Center at USF. "After a few years, many patients find that their traditional Parkinson's disease medications wear off after a few hours leading to a re-emergence of symptoms. In this study, preladenant was shown to reduce off time, thereby affording patients more time through the day with better function."

Dr. Hauser and colleagues evaluated the safety and effectiveness of a range of doses of preladenant in 253 patients experiencing "wearing off" symptoms from their levodopa therapy. The patients were also receiving other available anti-parkinsonian drugs, such as dopamine agonists and/or entacapone.

The 12-week study found that the addition of 5 and 10 mg of preladenant twice daily significantly reduced "off time" -- the re-emergence of troublesome motor symptoms such as slowness, stiffness, tremors, and immobility – when compared to patients receiving similar doses of placebo. Futhermore, preladenant significantly increased "on time" – the period during which patients' Parkinson's symptoms were adequately controlled --.without significantly worsening dyskinesia (involuntary twisting, turning movements). The doses were well tolerated, and the incidence of treatment-related adverse effects was similar for patients receiving preladenant and placebo.

In Parkinson's disease, the brain's dopamine-producing cells falter and die, leading to movement-related or motor symptoms such as tremors, stiffness, slowness, and balance problems.

Levodopa, a compound converted into dopamine in the brain, is still the gold standard therapy for Parkinson's, but as the disease advances this standard drug works for increasingly shorter time periods. As a result, patients begin to experience impaired movement before their next scheduled dose of medication. The re-emergence of symptoms accompanying this "off-time" can make it difficult for patients to perform even the most basic functions, such as walking and dressing. In addition, over time patients tend to develop a sensitivity to levodopa therapy during "on-time" resulting in involuntary twisting, turning movements known as dyskinesia.

Currently available drugs widely used to treat Parkinson's disease correct for the loss of the neurotransmitter dopamine – either by boosting available dopamine in the brain or directly stimulating dopamine receptors. New ways to treat the disease that better address motor fluctuations without adverse side effects continue to be sought. Preladenant is a non-dopaminergic medication that targets adenosine A2A receptors in the motor control areas of the brain. It may offer advantages over dopamine medications, possibly including fewer side effects.

The clinical trial was conducted at 44 sites in 15 countries. Preladenant is an investigational medicine and is not approved for use.

### Funding for the study was provided by Schering-Plough, a subsidiary of Merck. Dr. Hauser has done consulting for Schering-Plough.

Parkinson's disease is an age-related, degenerative brain disease that affects one out of 100 people over age 60.

USF Health is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida's colleges of Medicine, Nursing, Public Health and Pharmacy, the School of Biomedical Sciences and the School Physical of Therapy and Rehabilitation Sciences; and the USF Physician's Group. With more than $394.1 million in research grants and contracts in FY2009/2010, the University of South Florida is a high impact global research university.

ELSE PRESS RELEASES FROM THIS DATE:

Lake-effect theory sinks, but quake timing questions go on

2011-02-14

EUGENE, Ore. -- (Feb. 10, 2011) -- A chronology of 1,000 years of earthquakes at the southern end of the San Andreas Fault nixes the idea that lake changes in the now-dry region caused past quakes. However, researchers say, the timeline pulled from sediment in three deep trenches confirms that this portion of the fault is long past the expected time for a major temblor that would strongly shake the Los Angeles Basin. The new study, appearing in the February issue of the Bulletin of the Seismological Society of America, doesn't change existing thinking about the threat ...

Homogeneous tuberculosis treatment ineffective in children, UT Southwestern researchers find

2011-02-14

DALLAS – Feb. 10, 2011 – The realization of medically treating different children uniquely may start with one of the deadliest diseases in existence: tuberculosis. New findings by UT Southwestern Medical Center researchers indicate that the type of medications and the dosage routinely used to treat children with the disease should be individualized to each young patient in order to be effective. The findings, available online and in the February issue of Antimicrobial Agents and Chemotherapy, show that currently recommended doses are much too low and that a child's ...

SMFM highlights significance of spina bifida research findings

2011-02-14

SAN FRANCISCO (February 10, 2011) — More than two thousand physicians, some of the top obstetric/gynecologists in the world who specialize in maternal-fetal medicine, especially high risk pregnancies, gathered today for their annual meeting in San Francisco to begin four days of intensive research presentations. Presentations each year at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting, The Pregnancy Meeting ™, represent major findings in reducing high-risk pregnancies and complications. Catherine Y. Spong, M.D., chief, pregnancy and perinatology branch, ...

SLU research implicates natural toxin as triggering Parkinson's disease

2011-02-14

ST. LOUIS – In new research from Saint Louis University, investigators have found evidence that a toxin produced by the brain is responsible for the series of cellular events that lead to Parkinson's disease. The study, published in PLoS One, found that the brain toxin DOPAL plays a key role in killing the dopamine neurons which trigger the illness. In earlier research, Saint Louis University investigators found that DOPAL seemed to be responsible for killing healthy dopamine cells, which in turn causes Parkinson disease to develop. Now, research in an animal model ...

LED products billed as eco-friendly contain toxic metals, study finds

2011-02-14

Irvine, Calif., Feb. 10, 2011 – Those light-emitting diodes marketed as safe, environmentally preferable alternatives to traditional lightbulbs actually contain lead, arsenic and a dozen other potentially hazardous substances, according to newly published research. "LEDs are touted as the next generation of lighting. But as we try to find better products that do not deplete energy resources or contribute to global warming, we have to be vigilant about the toxicity hazards of those marketed as replacements," said Oladele Ogunseitan, chair of UC Irvine's Department of Population ...

When nature calls

2011-02-14

COLLEGE STATION, Feb. 9, 2011 — When you've got to go, you've got to go — upstream, that is, if you are a male swordtail fish seeking a mate, according to research from Texas A&M University. A recent study led by Texas A&M biologists Dr. Gil Rosenthal and Dr. Heidi Fisher in collaboration with scientists at Centro de Investigaciones Cientificas de las Huastecas in Hidalgo, Mexico, and Boston University has determined that the fish use chemical cues in their urine to elicit sexual responses from their downstream female counterparts. In a study funded by the National ...

New model reveals pesticide-free method that takes a bite out of mosquito-borne disease

2011-02-14

Scientists have modeled a system that may be used to control mosquitoes and the diseases they transmit, without the use of pesticides. In the proposed system, mosquitoes are engineered to carry two genes. The first gene causes males to transmit a toxin to females through their semen. The second gene, when expressed in females, makes them immune to this toxin. This research, published in the February 2011 issue of Genetics (http://www.genetics.org), describes a system that can be created using currently available molecular tools and could confine the spread of mosquitoes ...

UCSB chemists make discovery that may lead to drug treatment possibilities for Alzheimer's

2011-02-14

(Santa Barbara, Calif.) –– UC Santa Barbara scientists have made a discovery that has the potential for use in the early diagnosis and eventual treatment of plaque-related diseases such as Alzheimer's disease and Type 2 diabetes. Their work is published in a recent issue of Nature Chemistry. The amyloid diseases are characterized by plaque that aggregates into toxic agents that interact with cellular machinery, explained Michael T. Bowers, lead author and professor in the Department of Chemistry and Biochemistry. Other amyloid diseases include Parkinson's disease, Huntington's ...

Pulmonary fibrosis inhibited by pentraxin-2/SAP in research study

2011-02-14

MALVERN, PA – February 10, 2011 – Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology entitled, "TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P." The research showed that human Pentraxin-2 (PTX-2), also called human Serum amyloid P (SAP), potently inhibits all undesirable pro-fibrotic pathologies driven by TGFβ1 and represents a novel ...

Chinks in the brain circuitry make some more vulnerable to anxiety

2011-02-14

Why do some people fret over the most trivial matters while others remain calm in the face of calamity? Researchers at the University of California, Berkeley, have identified two different chinks in our brain circuitry that explain why some of us are more prone to anxiety. Their findings, published today (Thursday, Feb. 10) in the journal Neuron may pave the way for more targeted treatment of chronic fear and anxiety disorders. Such conditions affect at least 25 million Americans and include panic attacks, social phobias, obsessive-compulsive behavior and post-traumatic ...

Non-dopaminergic drug preladenant reduces motor fluctuations in patients with Parkinson's disease

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: